IE914326A1 - Oral administration of alpha interferon to treat lung¹malignancies - Google Patents
Oral administration of alpha interferon to treat lung¹malignanciesInfo
- Publication number
- IE914326A1 IE914326A1 IE432691A IE432691A IE914326A1 IE 914326 A1 IE914326 A1 IE 914326A1 IE 432691 A IE432691 A IE 432691A IE 432691 A IE432691 A IE 432691A IE 914326 A1 IE914326 A1 IE 914326A1
- Authority
- IE
- Ireland
- Prior art keywords
- treating
- preventing
- alpha interferon
- pharmaceutical composition
- mammal
- Prior art date
Links
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 30
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 210000004072 lung Anatomy 0.000 claims abstract description 38
- 241000282414 Homo sapiens Species 0.000 claims abstract description 32
- 230000036210 malignancy Effects 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 241000124008 Mammalia Species 0.000 claims abstract description 22
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000006199 nebulizer Substances 0.000 claims abstract description 6
- 229940071648 metered dose inhaler Drugs 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 102000014150 Interferons Human genes 0.000 claims description 12
- 108010050904 Interferons Proteins 0.000 claims description 12
- 229940079322 interferon Drugs 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims description 2
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 108010078049 Interferon alpha-2 Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003507 interferon alfa-2b Drugs 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010022004 Influenza like illness Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 235000019506 cigar Nutrition 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019505 tobacco product Nutrition 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000002365 Viral Bronchiolitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 108700028467 human IFNA1 Proteins 0.000 description 1
- 102000051101 human IFNA1 Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical composition for treating or preventing lung malignancy in mammal comprising recombinant DNA human alpha interferon (rhIFN- alpha ), a use of rhIFN- alpha for the manufacture of a medicament for treating or preventing a lung malignancy in mammals as well as a method of treating or preventing a lung malignancy in a mammal by administering by oral inhalation to such a mammal afflicted with a lung malignancy an effective amount of rhIFN- alpha via a nebulizer or metered dose inhaler are disclosed.
Description
ORAL ADMINISTRATION OF ALPHA INTERFERON TO TREAT LUNG MALIGNANCIES SCHERING CORPORATION, a corporation organized and existing under the laws of the State of New Jersey, United States of America, of 2000 Galloping Hill Road, Kenilworth, New Jersey, 07033, United States of America 5015 -1OC0129 ORAL ADMINISTRATION OF ALPHA INTERFERON TO TREAT LUNG MALIGNANCIES BACKGROUND OF THE INVENTION This invention relates to pharmaceutical compositions comprising human alpha interferon (hIFN-a) as an active ingredient to treat lung malignancies in mammals. The invention also relates to the use of hIFN-a for making medicaments for treating lung malignancies in mammals as well as to methods of treating lung malignancies, generally referred to as lung cancer, by administering by oral inhalation to a mammal in need of such treating an amount of human alpha in recombinant DNA human alpha interferon (rhIFN-α) effective for such treating.
Human alpha interferon (hIFN-α) is a naturally occurring mixture of at least eleven compounds including those designated alpha-1 interferon and alpha-2 interferon.
A number of alpha interferon species or components are known and are usually designated by a numeral and letter after the Greek letter alpha. Human alpha-1 interferon is one species contemplated for use in this invention as are the species designated human alpha2 interferons. Under USAN, recombinant DNA human alpha-2 interferons are designated Interferon Alpha-2a, which can -2be made as disclosed in Rubenstein, Biochem. Biophys.
Acta (1982), 695, 5-16, and Interferon Alfa-2b.
Interferon Alfa-2b is the preferred species for use in this invention and is a recombinant DNA human alpha interferon (hereinafter *rhIFN-a*). Another suitable rhIFN-a included in the acope of this invention is recombinant DNA human interferon alpha-2a.
Human interferon alfa-2b can be produced in bacteria and other microorganisms using recombinant DNA techniques including those disclosed in Nagata et al. Nature, (1980) 284, 316-329; European Patent 32,134 and U.S. Patent No. 4,289,690. Various alpha interferon species are disclosed in U.S. patent 4,503,035.
It is known to administer rhIFN-a parenterally to treat hairy cell leukemia, AIDS-related Kaposi's sarcoma, and hepatitis as well as intralesionally to treat condylomate acuminata. Several groups of investigators have documented that parenterally administered IFN-a does not accumulate in the nasopharyngeal, oropharyngeal, or airway mucosa or in the lung parenchyma in sufficient concentrations or for long enough time periods to be effective against respiratory virus infections.
Recently, it has been shown that nonrecombinant human leukocyte alpha-interferon (hereinafter *hIFN-a*) can be given to mammals by inhalation to provide high local concentrations in lung and airway mucosal tissue. Nebulized hIFN-α inhibits viral replication in mice (Please give Reference). The instillation of hIFN-α into the bronchi of perfused rabbit lungs has resulted in measurable serum concentrations [V. Bocci et al., Antiviral Res. (1984) Vol. 4, 211-220].
Intranasally administered rhIFN-α at a dose of 5 million units/day prevented rhinovirus transmission -3within families (Douglas, et al, NEJM (1986), Vol. 314, pp65-70. In one Chinese study, interferon-a (hIFN-a) given both intranasally and intraorally at a dose of 7001600 units/day was effective in the treatment of influenza, respiratory syncytial viral bronchiolitis, and asthmatic bronchitis (Jia-xiong, et al, Chin Med J. 100:162-166, 1987).
In man, hIFN-α has been inhaled by patients with advanced non-small cell lung cancer at doses up to 120 million International Units (IU). Kinnula et al. discloses in the J. Interferon Res. (1989), Vol 9, 419-23 that inhaled hIFN-α resulted in serum concentration and side effects (e.g. fever, headache, influenza-like symptoms and nausea) similar to those disclosed after systemic hIFN-α administration as well as reversible airflow obstruction but no activity against the lung cancer was observed. Inhaled hIFN-α has also been administered to patients suffering from bronchoalveolar carcinoma but no activity on the bronchoalveolar carcinoma has been demonstrated [V. Kinnula et al. J. Interferon Res, (1988) Vol 8, Suppl. 1 pll5] In-vitro activity of rhINF-α A (Roferon) and rhIFN-aD in various human tumor cell assays including lung cancer is known [S.E. Salmon et al., J. Clin. Oncology (1983) Vol. I. p217-225]. Human leukocyte interferon (hIFN-α) exhibited inhibition of colony formation of greater than 70% against only five including 2 lung tumors of the sixty-two tumor types in an in vitro assay (D.D. Von Hoff et al. Cancer Chemother. Pharmacol. (1982), Vol. 8, 99-103.
SUMMARY OF THE INVENTION The present invention provides a pharmaceutical composition for treating or preventing a lung malignancy in a mammal which composition comprises an effective amount of recombinant DNA human alpha interferon. -4The present invention also provides a use of recombinant DNA human alpha interferon for the manufacture of a medicament for treating or preventing a lung malignancy in a mammal.
This invention also provides a method of treating a lung malignancy in a mammal afflicted with such malignancy which comprises administering via oral inhalation to such a mammal an amount of recombinant human DNA alpha interferon effective for such treating. This invention also provides a method of preventing a lung malignancy in a mammal susceptible to lung malignany - e.g. heavy smokers of any tobacco products especially cigars and cigarettes, which comprises administering via oral inhalation to such a mammal an amount of recombinant DNA human alpha interferon effective for such preventing.
DETAILED DESCRIPTION OF THE INVENTION The term lung malignancy as used herein means at least one of squamous cell carcinoma, large cell carcinoma, small cell carcinoma, alveolar cell carcinoma, bronchoalveolar carcinoma, adenocarcinoma, bronchogenic carcinoma-in-situ, metastatic carcinoma, or sarcoma from primary tumors outside the lung or airways.
The effectiveness of the interferon therapy of this invention can be shown clinically in mammals, e.g, human beings afflicted with a lung malignancy or suspectible to a lung malignancy due to the smoking tobacco products, especially cigarettes and/or cigars using patients with the following entry criteria: (1) a Karnofsky performance status of 60%; (2) adequate pulmonary function for undergoing the required inhalation treatment satisfactorily as evidenced by (a) forced expiration volume in one second (FEVj) of greater than or equal to 40% and (b) a forced vital capacity (FVC) of greater than or equal to 50% of the -5predicted value and; (3) no serious systemic infections and/or fever.
The recombinant DNA human alpha interferon (rhIFN-α) administered via oral inhalation in accordance with this invention may be used as monotherapy or as adjunctive therapy with other treatments e.g., chemotherapy or immunotherapy to treat lung malignancy and prevent, inhibit and/or cure the pulmonary metastatic spread of one or more of the types of lung malignancies listed hereinabove. The list of conventional chemotherapeutic agents useful in combination with alpha interferon is disclosed by S. Wadler et al in Cancer Research (1990), Vol 50 pp 5472-3486.
The recombinant DNA human alpha interferon (*rhIFN-a*) is administered by oral inhalation in accordance with this invention as a pharmaceutical composition containing rhIFN-α which may be dissolved or dispersed in a pharmaceutically acceptable carrier suitable for use in a nebulizer and/or a metered dose inhaler. Pharmaceutically acceptable carriers include, for example, water, saline, ethanol and the like which form a rhIFN-α solution or suspension suitable for administration via oral inhalation in accordance with this invention. If desired, the rhIFN-α pharmaceutical composition useful in this invention may also contain minor amounts of non-toxic auxiliary substances such as melting agents, emulsifying agents, preservatives, stabilizers, and pH buffering agents. The preparation of these pharmaceutical compositions is well known to those skilled in the art; see for example Remington's Pharmaceutical Sciences Mack Publishing Co., Easton PA 15th Edition (1975).
A preferred rhIFN-α pharmaceutical composition for use in accordance with this invention is the Intron® A brand of interferon available as a solution from -6Schering-Plough Corporation, Kenilworth, New Jersey.
This commercially available Intron A rhIFN-α composition contains glycine, di- and mono- basic sodium phosphate as a buffer and serum albumin. Other preferred rhIFN-a pharmaceutical compositions include any sterile isotonic aqueous solution, e.g. physicological phosphate-buffered saline at pH 7.3 which may also contain pharmaceutically acceptable non-toxic auxiliary agents such as stabilizers and/or a surfactants and the desired amount of rhIFN-a. The concentration of rhIFN-α in the pharmaceutical composition may be adjusted by dilution with 0.9% saline solution before administration via oral inhalation. The oral inhalation of drugs by use of nebulizers and metered dose inhalers is well known. See for example Remington, ibid, at chapter 99, pages 1910-1912. Useful nebulizers include the Spira Electro 4 nebulizer, manufactured by Hameenlinman Tyoleskus, Hameenlinna, Finland, whose use is disclosed by Kinnula et al. in the J. of Interferon Research (1989) Vol. 9 at p420. Useful metered dose inhalers as well as drug delivery systems that help deliver oral aerosolized medications from metered dose inhalers to the lungs include INHAL-AID and INSPIREASE drug delivery systems available from Schering-Plough Corporation, Kenilworth, New Jersey, U.S.A, for as well as those disclosed in the Physicians Desk Reference, 1990 Edition, for use with bronchodilators. The output of the nebulizer or metered dose inhaler for use in this invention should consistently and reliably produce particles and/or droplets having a mass median aerodynamic diameter (M.M.A.D.) above about 0.5 microns, preferably having a M.M.A.D. above about 0.5 and less than about 8 microns and more preferably having a M.M.A.D above about 0.5 to about 5.0 microns. Orally inhaled particles and/or droplets containing rhIFN-α having a M.M.A.D in the range of above about 0.5 to less than -7about 8 microns are suitable for deposition on the peripheral airways and lungs and thus maximize the beneficial effects of inhaled rhIFN-α. Droplets and particles having a M.M.A.D. greater than 8 microns become impacted in the upper airways; and those having a M.M.A.D. less than about 0.5 microns tend to behave like a gas and are exhaled. However, droplets and/or particles of rhIFN-α having the preferred M.M.A.D. have a high surface energy and tend to agglomerate. The addition of a surfactant preferably a non-volatile liquid soluble in the propellant used in nebulizers or metered dose inhalers is desirable to lessen such agglomeration.
The effective amount of rhIFN-α for treating and/or preventing a lung malignancy in accordance with this invention is a dosage range of rhIFN-α of about 1 x 106 international units (IU) to about 1 x 1011 IU, preferably about 1 x 106 IU to about 5 x 1010 IU, and more preferably about 1 χ 10θ IU to about 2 χ ΙΟ^θ IU.
The rhINF-α maybe administered daily in single or divided doses.
Based on the judgment of the attending clinician, the amount of rhIFN-a administered and the treatment regimen used will, of course, be dependent on the age, sex and medical history of the patent being treated, the severity of the specific lung malignancy and the tolerance of patient to the treatment regimen as evidenced by local toxicity (e.g. nasal irritation and/or bleeding) and by systemic side effects (e.g. fever, malaire pancytopenia, CNS depression, gastrointestinal irritation and elevated liver enzymes).
The following is a description of the clinical protocol to be utilized for treating and preventing lung malignancies. -8Study Design Prior to enrollment, all patients are throughly examined and their disease clinically staged using chest x-rays, computerized tomography, EKG, hematologic and blood chemistries. Clotting studies including total fibrinogen determination, PTT, PT, TT, and fibrin degradation products are conducted. Karnofsky performance status, pulmonary function including peak expiratory flow (PEF), forced expiratory volume in one second (FEV·^) , and forced vital capacity (FVC) are measured. Subjective and objective symptoms including the number and severity of coughing bouts, shortness of breath, pain and coughing-up of blood as well as body temperature, blood pressure, and heart rate are measured.
Serum rhIFN-a Concentrations Serum rhIFN-α concentrations are determined by use of commercially available immunoradiometric assays (Abbott Diagnotics and Centocor, respectively) or by vesicular stomatitis virus (VSV) plaque reduction in HEp2 cultures. Measurement are performed before inhalation and 2hr, 5hr, lOhr, 15hr and 24 hr after inhalation.
Toxicity Evaluation and Response Criteria Each patient is vigorously monitored for early signs of toxicity as well as radiographic evidence of clinical effectiveness throughout the treatment course and on a regular basis thereafter. Methods of evaluation include frequent physician examination, a regular schedule for performance of laboratory procedures including hematologic and serum chemistries pulmonary function and clotting studies. Radiographic studies include chest x-rays and CT scans as appropriate.
Toxicity is graded in accordance with the Work Health Organization's recommendations for grading of acute and -9subacute toxicity. Performance status is graded from zero to four with complete disability being defined as four. Tumor response is determined by means of serial radiographic studies. Areas of referenced tumors are determined by multiplication of the longest diameter by the greatest perpendicular diameter. Complete response would be then defined as the disappearance of all measurable disease determined by observation separated by at least four weeks with the appearance of no new lesions within the radiation portal. Partial response is a 50% decrease in the referenced tumor mass and stable disease would be defined as a less than 50% decrease in tumor size, or less than 25% increase. A tumor growth larger than 25% is considered progressive disease.
Other response criteria include relief of subjective and objective symptoms especially a significant reduction in (1) the number and severity of coughing bouts (2) the shortness of breath, and (3) coughing-up of blood. Weight gain, increase in pulmonary capacity, exercise capacity and reduction in adjuntive or comcomitant cancer therapies would also indicate effective treatment.
Symptoms and objective side effects of rhIFN-a therapy including changes in body temperature, airflow obstructure and flu-like symptom are also measured.
A reduction in tumor growth and/or lung malignancy by administering by oral inhalation rhIFN-α to patients in need of such administer is expected.
Claims (14)
1. A pharmaceutical composition for treating or preventing a lung malignancy in a mammal which composition comprises an effective amount of recombinant DNA human alpha interferon.
2. A use of recombinant DNA human alpha interferon for the manufacture of a medicament for treating or preventing a lung malignancy in a mammal.
3. A method of treating a lung malignancy in a mammal afflicted with a lung malignancy which comprises administering by oral inhalation to such a mammal an amount of recombinant DNA human alpha interferon effective for such treating.
4. A method of preventing a lung malignancy in a mammal susceptible to a lung malignancy which comprises administering by oral inhalation to such a mammal an amount of recombinant DNA human alpha interferon effective for such preventing.
5. A pharmaceutical composition or a use or method of any preceding claim wherein the lung malignancy is selected from the group of squamous cell carcinoma, large cell carcinoma, small cell carcinoma, alveolar cell carcinoma, bronchoalveolar carcinoma, adenocarcinoma, bronchogenic carcinoma-in-situ, metastic carcinoma or sarcoma from primary tumors outside the lung or airways.
6. A pharmaceutical composition or use or method of treating or preventing of any preceding claim wherein the — 11 — recombinant DNA human alpha interferon is administered by a nebulizer.
7. A pharmaceutical composition or a use or a method of treating or preventing any of the preceding claims wherein the recombinant DNA human alpha interferon is administered by a metered dose inhaler.
8. A pharmaceutical composition or a use or method of treating or preventing any of the preceding claims wherein the recombinant human DNA alpha interferon is interferon alpha-2a.
9. A pharmaceutical composition or a use or method of treating or preventing any of the preceding claims wherein the recombinant human DNA alpha interferon is interferon alpha-2b.
10. A pharmaceutical composition or a use or method of treating or preventing any of the preceding claims where the amount of recombinant human DNA alpha interferon is in the range of about 1 x 10 6 IU to about 1 x 10 11 IU.
11. A pharmaceutical composition or a use or method of any of the preceding claim wherein the output of the nebulizer metered dose inhaler is in the form of particles of an aqueous solution of recombinant human alpha interferon having a mass median aerodynamic diameter of above about 0.5 to about 5.0 microns.
12. 12. A pharmaceutical composition as defined in Claim 1, substantially as described herein by way of Example.
13. Use of recombinant DNA human alpha interferon for the manufacture of a medicament, substantially as described herein by way of Example.
14. A method of treating a lung malignancy in a mammal substantially as described herein by way of Example.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62824090A | 1990-12-14 | 1990-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE914326A1 true IE914326A1 (en) | 1992-06-17 |
Family
ID=24518070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE432691A IE914326A1 (en) | 1990-12-14 | 1991-12-12 | Oral administration of alpha interferon to treat lung¹malignancies |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0563177A1 (en) |
| JP (1) | JPH06503570A (en) |
| AU (1) | AU9139091A (en) |
| CA (1) | CA2098393A1 (en) |
| EE (1) | EE9400337A (en) |
| IE (1) | IE914326A1 (en) |
| IL (1) | IL100332A0 (en) |
| MX (1) | MX9102512A (en) |
| PT (1) | PT99784A (en) |
| WO (1) | WO1992010207A1 (en) |
| ZA (1) | ZA919769B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9213322D0 (en) * | 1992-06-23 | 1992-08-05 | Efamol Holdings | Antioxidant compositions |
| ES2161793T3 (en) * | 1994-04-09 | 2001-12-16 | Hoffmann La Roche | PROCESS FOR THE PRODUCTION OF ALFA-INTERFERONA. |
| AUPN976596A0 (en) * | 1996-05-09 | 1996-05-30 | Pharma Pacific Pty Ltd | Stimulation of host defence mechanisms |
| US6207145B1 (en) | 1997-05-09 | 2001-03-27 | Pharma Pacific Pty Ltd. | Therapeutic applications of high dose interferon |
| CN1151840C (en) * | 1996-05-09 | 2004-06-02 | 太平洋制药控股公司 | Stimulation of host defence mechanisms against tumors |
| ATE316792T1 (en) * | 1996-05-09 | 2006-02-15 | Pharma Pacific Pty Ltd | STIMULATION OF THE HOST'S OWN DEFENSE MECHANISMS AGAINST CANCER |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| AU2002330801A1 (en) * | 2002-06-20 | 2004-01-06 | Igor Anatolievich Pomytkin | Method for oral transmucosal delivery of interferon |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077063B1 (en) * | 1981-10-13 | 1988-03-16 | Exovir, Inc. | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
| AU634511B2 (en) * | 1988-12-01 | 1993-02-25 | Schering Corporation | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
-
1991
- 1991-12-11 CA CA002098393A patent/CA2098393A1/en not_active Abandoned
- 1991-12-11 MX MX9102512A patent/MX9102512A/en unknown
- 1991-12-11 ZA ZA919769A patent/ZA919769B/en unknown
- 1991-12-11 JP JP4502377A patent/JPH06503570A/en active Pending
- 1991-12-11 AU AU91390/91A patent/AU9139091A/en not_active Abandoned
- 1991-12-11 IL IL100332A patent/IL100332A0/en unknown
- 1991-12-11 WO PCT/US1991/009084 patent/WO1992010207A1/en not_active Application Discontinuation
- 1991-12-11 EP EP92901697A patent/EP0563177A1/en not_active Withdrawn
- 1991-12-12 PT PT99784A patent/PT99784A/en not_active Application Discontinuation
- 1991-12-12 IE IE432691A patent/IE914326A1/en not_active Application Discontinuation
-
1994
- 1994-11-21 EE EE9400337A patent/EE9400337A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX9102512A (en) | 1992-06-01 |
| EP0563177A1 (en) | 1993-10-06 |
| IL100332A0 (en) | 1992-09-06 |
| EE9400337A (en) | 1996-02-15 |
| ZA919769B (en) | 1992-09-30 |
| JPH06503570A (en) | 1994-04-21 |
| PT99784A (en) | 1992-12-31 |
| CA2098393A1 (en) | 1992-06-15 |
| WO1992010207A1 (en) | 1992-06-25 |
| AU9139091A (en) | 1992-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5618786A (en) | Aerosolization of protein therapeutic agent | |
| EP0505123B1 (en) | Pulmonary administration of granulocyte colony stimulating factor | |
| US5354934A (en) | Pulmonary administration of erythropoietin | |
| US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
| Knight et al. | Ribavirin aerosol treatment of influenza | |
| JPH05501263A (en) | Aerosol formulation of glutathione | |
| IE914326A1 (en) | Oral administration of alpha interferon to treat lung¹malignancies | |
| Kinnula et al. | Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma | |
| Podzamczer et al. | Low‐dose interferon alpha combined with zidovudine in patients with AIDS‐associated Kaposi's sarcoma | |
| JPH02264730A (en) | Inhalant for treating atll | |
| HU207229B (en) | Process for producing pharmaceutical compositions containing gm-csf for treating leukocyte disfunction | |
| Can et al. | Salbutamol or mist in acute bronchiolitis | |
| US20210353650A1 (en) | Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation | |
| IE914444A1 (en) | Administering alpha interferon by oral inhalation to treat¹asthma and non-malignant proliferative pulmonary diseases | |
| Reiser et al. | Inhalation treatment for asthma. | |
| US6030609A (en) | Method and composition for treating paramyxovirus | |
| JP2759050B2 (en) | Pharmaceutical composition for treating sudden deafness | |
| Hockley et al. | Fenoterol versus salbutamol nebulization in asthma | |
| Douglas et al. | A comparative study of two doses of salbutamol nebulized at 4 and 8 litres per minute in patients with chronic asthma | |
| US20240009227A1 (en) | Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route | |
| JPWO2021211885A5 (en) | ||
| TR2023001534T2 (en) | USE OF A HEPARIN COMPOUND IN THE TREATMENT OF VIRAL LUNG DISEASES, INCLUDING COVID-19, AND ACUTE AND/OR CHRONIC LUNG DISEASES BY INHALE VIA A SOFT MIST INHALER OR VIBRATION SIEVE TECHNOLOGY NEBULIZER. | |
| RU1801495C (en) | Method for treatment of acute infectious destruction of lungs | |
| Susskind | Inhalation delivery of drugs | |
| TR202012816A2 (en) | Use of anticoagulants via soft mist inhaler in symptoms caused by new type of covid-19. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Application refused sect. 31(1) |